BlossomHill Therapeutics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $BLSM in the last 7 days.
No SEC Form 4 filings for $BLSM in the last 30 days.
See all $BLSM insider activity →Amneal Pharmaceuticals (AMRX) rose 7% to $21.17 after FDA approval for a generic Lanreotide injection. BlossomHill Therapeutics (BLSM) climbed 6% to $27.99 following positive Phase 1/2 study results. Neogen (NEOG) increased 2% to $13.34 after reporting Q4 revenue of $225M. NeoGenomics (NEO) hit a 52-week high of $20.05 after announcing Medicare and Medicaid coverage for its RaDaR ST test.
BlossomHill Therapeutics (BLSM) reported a wider Q2 2026 loss of $23.8M, with R&D expenses rising to $21.4M. The FDA granted Fast Track designation to BH-30643 for NSCLC treatment. The company expects to fund operations into Q2 2028 following a $168.3M IPO. BH-30643 showed 45% response rate in trials.
BlossomHill Therapeutics reported a net loss of $23.8M for Q3 2026, widening from a $13.2M loss a year ago, with no revenue as it remains in clinical stages. The company is progressing with multiple clinical trials and expects IPO proceeds to fund operations into Q2 2028.
Recent BLSM coverage spans technology, market movers and regulation.
Strong early trial results may accelerate development and attract investors.
Fast Track status and strong early efficacy data could accelerate development and boost investor confidence.
The wider-than-expected loss may pressure the stock, but the expanded pipeline could support long‑term upside.
Positive regulatory milestone and cash runway may support near‑term price appreciation.
Positive regulatory milestone and strong early efficacy data likely boost near‑term demand and support a price rally.
AlphAI scores every news story that mentions BLSM with an AI model for sentiment and relevance, and aggregates insider trades from BlossomHill Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Amneal Pharmaceuticals (AMRX) rose 7% to $21.17 after FDA approval for a generic Lanreotide injection. BlossomHill Therapeutics (BLSM) climbed 6% to $27.99 following positive Phase 1/2 study results. Neogen (NEOG) increased 2% to $13.34 after reporting Q4 revenue of $225M. NeoGenomics (NEO) hit a 52-week high of $20.05 after announcing Medicare and Medicaid coverage for its RaDaR ST test.
2 min readBlossomHill Therapeutics (BLSM) reported a wider Q2 2026 loss of $23.8M, with R&D expenses rising to $21.4M. The FDA granted Fast Track designation to BH-30643 for NSCLC treatment. The company expects to fund operations into Q2 2028 following a $168.3M IPO. BH-30643 showed 45% response rate in trials.
2 min readBlossomHill Therapeutics reported a net loss of $23.8M for Q3 2026, widening from a $13.2M loss a year ago, with no revenue as it remains in clinical stages. The company is progressing with multiple clinical trials and expects IPO proceeds to fund operations into Q2 2028.
1 min readBlossomHill Therapeutics, Inc. (BLSM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results Strengthened balance sheet with successful completion of upsized $168.3 million initial public offering Announced FDA Fast Track designation for BH-30643 for the treatment of advanced EGFR C797S-p
2 min readBlossomHill Therapeutics (BLSM) reported Q2 2026 results, including $168.3M from IPO, $95.4M in cash, and FDA Fast Track designation for BH-30643. The drug showed 45% response rate in lung cancer trials. R&D expenses rose to $21.4M, leading to a $23.8M net loss. The company expects funding into Q2 2028.
2 min readBiotech stocks BLSM, NEOG, ILMN, CBLL, and ADPT hit 52-week highs. BLSM rose 18% on positive trial data, NEOG grew 2% with Q4 revenue of $225M, ILMN reached $236 on 9.5% Q2 growth, CBLL hit $25.63 with Q2 revenue up 33%, and ADPT climbed 3% with full-year revenue forecast between $268M-$278M.
3 min readBlossomHill Therapeutics (BLSM) presented Phase 1/2 trial data showing its drug BH-30643 achieved a 45% response rate in EGFR C797S-positive NSCLC patients. The stock rose 6% following the announcement. The drug has FDA Fast Track designation, and experts note its potential for addressing treatment-resistant mutations.
2 min readBlossomHill Therapeutics (BLSM) stock rose 4.4% in pre-market trading after presenting positive Phase 1/2 trial data for BH-30643 at a lung cancer conference. The drug showed a 45% response rate in treatment-resistant patients. CEO J. Jean Cui also presented at an investment conference, and Guggenheim initiated coverage with a Buy rating and $30 price target. The stock is near its 52-week high of $23.37.
2 min readBlossomHill Therapeutics, Inc. (BLSM) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR ™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer 45% objective response rate a
2 min readBlossomHill Therapeutics (BLSM) will present updated Phase 1/2 SOLARA trial data on BH-30643, an investigational EGFR inhibitor, for EGFR-mutant NSCLC with C797S resistance at the 2026 World Conference on Lung Cancer. The FDA granted Fast Track designation to BH-30643 for this indication. The stock rose 4.22% to $21.74 on Monday and is up 6.62% in pre-market trading.
2 min read
